DK3006464T3 - Antiricin-antistoffer og anvendelser dera - Google Patents
Antiricin-antistoffer og anvendelser dera Download PDFInfo
- Publication number
- DK3006464T3 DK3006464T3 DK15173921.6T DK15173921T DK3006464T3 DK 3006464 T3 DK3006464 T3 DK 3006464T3 DK 15173921 T DK15173921 T DK 15173921T DK 3006464 T3 DK3006464 T3 DK 3006464T3
- Authority
- DK
- Denmark
- Prior art keywords
- ricin
- sequence
- antibody
- seq
- ser
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (9)
1. Isoleret eller oprenset antistof eller fragment deraf, der omfatter en variabel letkæde, der omfatter sekvensen af komplementaritetsbestemmende område (CDR) LI af sekvens KASQDVTAAVA (SEQ ID NO: 4); sekvensen af CDR L2 af sekvens SASYRYT (SEQ ID NO: 8); og sekvensen af CDR L3 af sekvens QQYYNTPLT (SEQ ID NO: 12), og en variabel tungkæde, der omfatter sekvensen af komplementaritetsbestemmende område (CDR) Hl af sekvens EHIIN (SEQ ID NO: 16); sekvensen af CDR H2 af sekvens LINPNSGGTNYNQKFKD (SEQ ID NO: 20); og sekvensen af CDR H3 af sekvens LRYDAAY (SEQ ID NO: 24), hvor det isolerede eller oprensede antistof eller fragment deraf specifikt genkender og binder til lectin-B-protein af ricintoksin.
2. Isoleret eller oprenset antistof eller fragment deraf ifølge krav 1, der omfatter: den variable letkædesekvens: DIELTQSHKFMSTSVGDRVSITCKASQDVTAAVAWYQQKPGQSPKLLIHSASYRYTGV PDRFTGSGSGSDFTFTISSVQAEDLAVYYCQQYYNTPLTFGAGTKLELKR (SEQ ID NO: 31) og den variable tungkædesekvens: QVQLQESGPELVKPGASMKISCKASGYSFTEHIINWVKQTHRENLEWIGLINPNSGGTN YNQKFKDKATLTVDTASNTAYMELLSLTSEDSAVYYCARLRYDAAYWGQGTTVTVS S (SEQ ID NO: 32).
3. Isoleret eller oprenset antistof eller fragment deraf ifølge krav 1, hvor det isolerede eller oprensede antistof eller fragment deraf er humaniseret.
4. Isoleret eller oprenset antistof eller fragment deraf ifølge et hvilket som helst af kravene 1 til 3, hvor antistoffet er et IgG.
5. Sammensætning, der omfatter ét eller flere end ét antistof eller fragment deraf ifølge et hvilket som helst af kravene 1 til 4 og en farmaceutisk acceptabel fortynder, excipiens eller bærer.
6. Sammensætning ifølge krav 5, hvor sammensætningen er en vaccinesammensætning.
7. Isoleret eller oprenset antistof eller fragment deraf ifølge et hvilket som helst af kravene 1 til 4 eller sammensætning ifølge krav 6 til anvendelse ved forebyggelse af skadelige virkninger forårsaget af ricineksponering eller ved behandling af eksponering for ricin.
8. Kombination af antistoffer eller fragmenter deraf ifølge et hvilket som helst af kravene 1 til 4 eller sammensætning ifølge krav 5, hvor kombinationen eller sammensætningen tilvejebringer en synergistisk virkning på ricin-neutraliserende aktivitet, hvor ét af antistofferne eller fragmenterne deraf er det isolerede eller oprensede antistof eller et fragment deraf som defineret i krav 1, og et andet isoleret eller oprenset antistof eller fragment deraf, der omfatter en variabel letkæde, der omfatter en CDR LI af sekvens KASQDINNYLR (SEQ ID NO: 2), en CDR L2 af sekvens RANRLVD (SEQ ID NO: 6) og en CDR L3 af sekvens LQYDEFPYT (SEQ ID NO: 10); og en variabel tungkæde, der omfatter CDR Hl af sekvens EYIIN (SEQ ID NO: 14), en CDR H2 af sekvens WFYPGSGDIKYNEKFKD (SEQ ID NO: 18), og eb CDR H3 af sekvens NGRWDDDYFDY (SEQ ID NO: 22), hvor fortrinsvis mindst ét af antistofferne eller fragmenterne deraf er humaniseret, til anvendelse ved forebyggelse af skadelige virkninger forårsaget af ricineksponering eller ved behandling af eksponering for ricin.
9. Isoleret eller oprenset antistof eller fragment deraf ifølge et hvilket som helst af kravene 1 til 4 eller sammensætning ifølge krav 5 til anvendelse ved bibringelse af immunitet mod ricin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495544P | 2011-06-10 | 2011-06-10 | |
| EP12797225.5A EP2718321A4 (en) | 2011-06-10 | 2012-01-31 | ANTI-FRICTION ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3006464T3 true DK3006464T3 (da) | 2018-09-17 |
Family
ID=47295287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16180361.4T DK3150632T3 (da) | 2011-06-10 | 2012-01-31 | Anti-ricin-antistoffer og anvendelser deraf |
| DK15173921.6T DK3006464T3 (da) | 2011-06-10 | 2012-01-31 | Antiricin-antistoffer og anvendelser dera |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16180361.4T DK3150632T3 (da) | 2011-06-10 | 2012-01-31 | Anti-ricin-antistoffer og anvendelser deraf |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9309305B2 (da) |
| EP (3) | EP2718321A4 (da) |
| CA (2) | CA2837357C (da) |
| DK (2) | DK3150632T3 (da) |
| ES (2) | ES2685821T3 (da) |
| WO (1) | WO2012167346A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10233256B2 (en) * | 2014-11-28 | 2019-03-19 | The Israel Institute of Biological Research (IIBR) | Antibodies directed to ricin toxin |
| US10208108B2 (en) | 2014-11-28 | 2019-02-19 | The Israel Institute of Biological Research (IIBR) | Antibodies directed to ricin toxin |
| EP3368076A4 (en) | 2015-10-30 | 2019-08-28 | Galaxy Biotech, LLC | HIGHLY POWERFUL ANTIBODIES BINDING TO DEATH RECEIVER 4 AND DEATH RECEIVER 5 |
| US11447789B2 (en) | 2016-12-01 | 2022-09-20 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Production in plants of ricin antibodies that bind to ricin B chain |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DK0628639T3 (da) | 1991-04-25 | 2000-01-24 | Chugai Pharmaceutical Co Ltd | Rekonstitueret humant antistof mod human interleukin-6-receptor |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5626844A (en) | 1991-11-04 | 1997-05-06 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibody against ricin A chain |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| US7473423B2 (en) | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| AU6094696A (en) | 1995-06-05 | 1996-12-24 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefor |
| US6111079A (en) | 1995-06-05 | 2000-08-29 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefore |
| AU2903999A (en) | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| US20060051355A1 (en) * | 1998-03-23 | 2006-03-09 | Van Oosterhout Ypke V | Methods and means for the treatment of immune-related diseases |
| EP1150688A4 (en) | 1998-10-19 | 2004-06-16 | Yeda Res & Dev | TREATING SYSTEMIC LUPUS ERYTHEMATODES BY REGULATING THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS |
| WO2001071005A2 (en) | 2000-03-24 | 2001-09-27 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| EP1456651B1 (en) | 2001-11-30 | 2008-05-07 | National Research Council Of Canada | Self-assembly molecules |
| PT3483183T (pt) | 2002-03-01 | 2021-06-02 | Immunomedics Inc | Imunoconjugado compreendendo anticorpos rs7 humanizados |
| US7541033B2 (en) * | 2003-01-24 | 2009-06-02 | Applied Molecular Evolution, Inc. | Humanized anti-IL-1β antibodies |
| EP1651269A2 (en) | 2003-07-25 | 2006-05-03 | United States Army Medical Research and Material Command | Monoclonal antibodies against ricin toxin and methods of making and using thereof |
| SI2463305T1 (sl) | 2006-01-12 | 2016-10-28 | Alexion Pharmaceuticals, Inc. | Protitelesa OX-2/CD200 in njihove uporabe |
| EP2097450A2 (en) | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2009014745A1 (en) | 2007-07-25 | 2009-01-29 | Alexion Pharmaceuticals, Inc. | Antibodies to cd200 and uses thereof in inhibiting immune responses |
| GB0723797D0 (en) | 2007-12-05 | 2008-01-16 | Immunosolv Ltd | Method |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| JP2013013327A (ja) | 2009-10-29 | 2013-01-24 | Actgen Inc | Ｍａｎｓｃ１蛋白質に結合し、抗癌活性を有する抗体 |
-
2012
- 2012-01-31 DK DK16180361.4T patent/DK3150632T3/da active
- 2012-01-31 US US14/122,366 patent/US9309305B2/en active Active
- 2012-01-31 EP EP12797225.5A patent/EP2718321A4/en not_active Withdrawn
- 2012-01-31 EP EP15173921.6A patent/EP3006464B1/en active Active
- 2012-01-31 DK DK15173921.6T patent/DK3006464T3/da active
- 2012-01-31 CA CA2837357A patent/CA2837357C/en active Active
- 2012-01-31 CA CA3081284A patent/CA3081284C/en active Active
- 2012-01-31 EP EP16180361.4A patent/EP3150632B1/en active Active
- 2012-01-31 ES ES15173921.6T patent/ES2685821T3/es active Active
- 2012-01-31 WO PCT/CA2012/000092 patent/WO2012167346A1/en active Application Filing
- 2012-01-31 ES ES16180361T patent/ES2785349T3/es active Active
-
2016
- 2016-04-01 US US15/088,944 patent/US10081672B2/en active Active
- 2016-04-01 US US15/088,801 patent/US9982040B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160207998A1 (en) | 2016-07-21 |
| EP3150632A2 (en) | 2017-04-05 |
| WO2012167346A1 (en) | 2012-12-13 |
| ES2785349T3 (es) | 2020-10-06 |
| US20160280773A1 (en) | 2016-09-29 |
| EP2718321A1 (en) | 2014-04-16 |
| US9309305B2 (en) | 2016-04-12 |
| CA3081284A1 (en) | 2012-12-13 |
| EP3150632B1 (en) | 2020-04-08 |
| US10081672B2 (en) | 2018-09-25 |
| EP3006464B1 (en) | 2018-08-01 |
| DK3150632T3 (da) | 2020-04-27 |
| EP3006464A1 (en) | 2016-04-13 |
| CA3081284C (en) | 2024-02-13 |
| ES2685821T3 (es) | 2018-10-11 |
| US9982040B2 (en) | 2018-05-29 |
| EP2718321A4 (en) | 2015-01-28 |
| EP3150632A3 (en) | 2017-07-12 |
| CA2837357C (en) | 2020-07-07 |
| US20140093504A1 (en) | 2014-04-03 |
| CA2837357A1 (en) | 2012-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10149903B2 (en) | Fully human antibody against respiratory syncytical virus | |
| US10081672B2 (en) | Anti-ricin antibodies and uses thereof | |
| CA2704119C (en) | Humanized anti-venezuelan equine encephalitis virus recombinant antibodies | |
| US20170158753A1 (en) | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species | |
| Avril et al. | Isolation of antibodies from non-human primates for clinical use | |
| CN116514960A (zh) | 一种呼吸道合胞病毒的全人源单克隆抗体及其应用 | |
| EP4353744A1 (en) | Antibody against respiratory syncytial virus and use thereof | |
| WO2022122788A1 (en) | Multispecific antibodies against severe acute respiratory syndrome coronavirus 2 | |
| US11440951B2 (en) | Therapeutic antibodies to Marburg virus | |
| HU et al. | Patent 2837357 Summary | |
| ES2649565T3 (es) | Inmunoglobulina G contra las toxinas del ántrax | |
| Lebedin et al. | SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody | |
| WO2023111796A1 (en) | Pan-specific sars-cov-2 antibodies and uses thereof | |
| US8501157B2 (en) | Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies | |
| WO2023150313A1 (en) | Multispecific binding protein compositions and uses thereof |